AI Drug Discovery
Alnylam Forges $2 Billion AI Alliance with Inceptive to Revolutionize RNA Drug Discovery
Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, has announced a significant strategic collaboration with Inceptive, an emerging force in artificial intelligence-driven drug discovery. This ambitious partnership, potentially valued at up to $2 billion, aims to revolutionize the identification and development of novel RNA-based medicines. The alliance underscores a